Barlow Wealth Partners Inc. Purchases Shares of 2,200 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Barlow Wealth Partners Inc. acquired a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 2,200 shares of the biopharmaceutical company's stock, valued at approximately $184,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Avior Wealth Management LLC increased its stake in shares of Intra-Cellular Therapies by 3.0% in the third quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company's stock worth $327,000 after acquiring an additional 131 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Intra-Cellular Therapies by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company's stock worth $748,000 after purchasing an additional 141 shares during the last quarter. Pallas Capital Advisors LLC raised its stake in shares of Intra-Cellular Therapies by 6.4% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company's stock worth $266,000 after purchasing an additional 192 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Intra-Cellular Therapies by 9.1% during the 3rd quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock valued at $181,000 after buying an additional 207 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D lifted its holdings in shares of Intra-Cellular Therapies by 0.6% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 35,673 shares of the biopharmaceutical company's stock valued at $2,610,000 after buying an additional 223 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intra-Cellular Therapies

In related news, President Michael Halstead sold 22,869 shares of the company's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently commented on ITCI. Royal Bank of Canada restated a "sector perform" rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday. Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Needham & Company LLC reiterated a "hold" rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Finally, Morgan Stanley raised their target price on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Seven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $102.15.

Intra-Cellular Therapies Trading Up 0.5 %

NASDAQ:ITCI traded up $0.65 during mid-day trading on Wednesday, hitting $127.15. 6,343,957 shares of the company's stock traded hands, compared to its average volume of 7,183,243. The firm has a market capitalization of $13.48 billion, a price-to-earnings ratio of -146.15 and a beta of 0.70. The firm has a 50 day moving average of $89.99 and a two-hundred day moving average of $81.30. Intra-Cellular Therapies, Inc. has a 12 month low of $62.78 and a 12 month high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. During the same period last year, the firm posted ($0.25) EPS. The company's revenue was up 39.0% compared to the same quarter last year. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.